Ashling Wahner

Associate Editor, OncLive

Ashling Wahner joined MJH Life Sciences in 2022. She produces OncLive's podcast, OncLive On Air, and helps ensure timely publication of news content and announcements from the FDA approval pipeline. She also attends conferences live and virtually to conduct video interviews and produce written coverage. Email: awahner@mjhlifesciences.com

Articles

Dr Awad on the FDA Approval of Perioperative Nivolumab for Resectable NSCLC

October 3rd 2024

Mark Awad, MD, PhD, discusses the significance of the FDA approval of perioperative nivolumab for patients with resectable NSCLC.

Bria-IMT Plus Immunotherapy Shows Early Promise in Breast Cancer Brain Metastasis

October 2nd 2024

Bria-IMT plus an immune checkpoint inhibitor completely resolved a breast cancer metastasis and shrunk an eye-bulging orbital lesion in 1 patient.

DCISionRT Biosignature Identifies Residual Recurrence Risk in HER2(3+) Breast Cancer

October 2nd 2024

DCISionRT identified patients with HER2-positive breast cancer at higher risk of residual disease following breast-conserving surgery plus radiotherapy.

Uncovering and Addressing Unmet Needs in Pediatric Cancer Care

October 2nd 2024

Saro H. Armenian, DO, MPH, discusses ongoing research that aims to enhance the quality of care for childhood cancer survivors.

Allogeneic T-Cell Therapy Produces Efficacy at 10 Months in Stage IV Metastatic NSCLC

October 1st 2024

Treatment with Deltacel was safe and showed antitumor activity at 10 months in a patient with stage IV metastatic non–small cell lung cancer.

Mezigdomide Plus Tazemetostat and Dexamethasone Is Effective and Safe in Refractory Myeloma

September 30th 2024

Mezigdomide, tazemetostat, and dexamethasone demonstrated early efficacy signals in patients with refractory multiple myeloma.

Board Review Resources 2024

September 30th 2024

Drs Armstrong and Tawagi discuss the board review plans they followed in the months leading up to their hematology and oncology board exams.

Bosutinib Yields Long-Term Efficacy and Safety in TKI-Pretreated CML

September 30th 2024

Treatment with bosutinib led to high response rates with a manageable safety profile in patients with CML who had previously received a TKI.

Belantamab Mafodotin Plus KRd Is Effective With Manageable Toxicities in R/R Multiple Myeloma

September 30th 2024

Belantamab mafodotin plus KRd was associated with a manageable safety profile and deep responses in pretreated patients with multiple myeloma.

Childhood Cancer Awareness Month Shines a Light on Treatment Interventions and Advancements

September 28th 2024

Saro H. Armenian, DO, MPH, raises awareness for childhood-related cancer interventions during Childhood Cancer Awareness Month.

Dr Koff on Frontine and Maintenance Treatment Decision-Making in MCL

September 27th 2024

Jean L. Koff, MD, MS, discusses factors that influence treatment decision-making for patients with MCL in the frontline and maintenance settings.

Dr Battiwalla on the Expanding Use of Bispecific Antibodies in NHL

September 27th 2024

Minoo Battiwalla, MD, MS, discusses the variety of bispecific antibodies evaluated for patients with NHL, including DLBCL.

Daratumumab Plus VRd Improves MRD Negativity in Newly Diagnosed, Transplant-Ineligible or -Deferred Myeloma

September 27th 2024

Daratumumab plus VRd improved MRD-negativity rates in transplant-ineligible or -deferred, newly diagnosed multiple myeloma.

Daratumumab/Lenalidomide Improves MRD– Conversion Rates in Newly Diagnosed Myeloma After ASCT

September 27th 2024

Daratumumab/lenalidomide maintenance increased MRD-negative conversion rates vs lenalidomide alone in newly diagnosed multiple myeloma after transplant.

Glucocorticoid Receptor Targeting With Relacorilant May Improve Ovarian Cancer Outcomes

September 27th 2024

Domenica Lorusso, MD, PhD, discusses the investigation of the glucocorticoid receptor modulator relacorilant plus nab-paclitaxel in ovarian cancer.

PAS-004 Has Tolerable Safety Profile and Preliminary Efficacy in MAPK-Driven Solid Tumors

September 27th 2024

The MEK inhibitor PAS-004 is safe, tolerable, and generated early efficacy signals in patients with MAPK pathway–driven advanced cancers.

Dendritic Cell–Based Immunotherapy Data in Resected Pancreatic Cancer Published in JCO

September 27th 2024

MesoPher cell therapy led to a 2-year recurrence-free survival rate of 64% and low-grade AEs in resected pancreatic cancer following chemotherapy.

How Luspatercept Could Shake Up MDS Management—With Rory Shallis, MD

September 26th 2024

Dr Shallis discusses the ELEMENT-MDS trial in MDS and the potential of intervening with luspatercept before patients become RBC transfusion dependent.

ODAC Votes Against Risk:Benefit Profile of Frontline Anti–PD-1 Therapy in Metastatic/Unresectable ESCC With a PD-L1 Expression Under 1

September 26th 2024

The FDA’s ODAC voted against the risk:benefit profile of anti–PD-1 therapy in first-line metastatic ESCC with a PD-L1 of less than 1.

Frontline SHR-1701 Plus CAPOX Delivers Superior OS vs CAPOX Alone in Gastric/GEJ Cancer

September 26th 2024

The addition of SHR-1701 to the HER2-negative gastric/GEJ cancer treatment paradigm may enhance the efficacy of current treatments for this population.